Diseases of the Immune System Flashcards
Results from activation of TH2 CD4+ helper T cells by environmental antigens, leading to the production of IgE antibodies, which become attached to mast cells; examples: Anaphylaxis, Allergies, Bronchial asthma
Type I Hypersensitivity (Immediate)
Caused by antibodies that bind to fixed tissue and cell antigens and promote phagocytosis and destruction of the coated cells or trigger pathologic inflammation in tissues; examples: Goodpasture syndrome, Autoimmune hemolytic anemia, Immune thrombocytopenia, Pemphigus vulgaris, ANCA vasculitides, Acute rheumatic fever, Graves disease, Myasthenia gravis, Insulin-resistant diabetes, Pernicious anemia, hyperacute and acute humoral rejection
Type II Hypersensitivity (Antibody-mediated)
Caused by antibodies binding to antigens to form complexes that circulate and may deposit in vascular beds and stimulate inflammation secondary to complement activation; examples: SLE, serum sickness, Arthus reaction, PSAGN, PAN, Reactive arthritis
Type III Hypersensitivity (Immune-complex mediated)
Cell-mediated immune responses in which T lymphocytes cause tissue injury, either by producing cytokines that induce inflammation and activate macrophages, or by directly killing cells; examples: Allergic contact dermatitis, Multiple sclerosis, Tuberculosis, PPD, RA, IBD, Acute cellular and chronic rejection, Type 1 DM and Hashimoto thyroiditis (the last two have Type 2 components as well)
Type IV Hypersensitivity (T-cell-mediated/delayed)
32/F presents to the clinic with symptoms of fatigue, joint pains, and malar rash. CBC revealed anemia and low platelet count. What is the diagnosis?
SLE
Hallmark of SLE.
Production of autoantibodies
Mechanisms of organ damage in SLE.
Type III (most); Type II (opsonization, hematologic manifestations)
Most common autoantibody in SLE.
ANA (98%)
Most specific autoantibodies for SLE.
anti-Sm (Smith), anti-dsDNA (anti-dsDNA correlates with disease activity)
Autoantibodies associated with congenital heart block in neonatal lupus.
Anti-Ro (SS-A), Anti-La (SS-B)
Histopathologic findings in SLE with skin involvement.
LM: Liquefactive degeneration of basal layer, edema at DEJ, mononuclear infiltrates around blood vessels and skin appendages IF: Deposition of Ig and complement at DEJ
Type of LE that associated with Hydralazine, INH, Procainamide, D-Penicillamine intake; rarely involves kidneys and brain; rarely associated with anti-dsDNA; associated with anti-histone antibodies.
Drug-induced lupus
Immune complexes in mesangium only; no alterations detectable by light microscopy.
Lupus nephritis Type I (Minimal mesangial)
Immune complexes in mesangium with mild to moderate increase in mesangial matrix and cellularity.
Lupus nephritis Type II (Mesangial proliferative)
Lesions visualized in fewer than half of the glomeruli, segmentally or globally distributed within each glomerulus; with cell proliferation, swelling, and infiltration of neutrophils and fibrinoid deposits.
Lupus nephritis Type III (Focal)
Most serious form and most commonly encountered; involvement of half or more glomeruli; with diffuse hypercellularity and wire-looping due to extnsive subendothelial deposits.
Lupus nephritis Type IV (Diffuse)
Widespread thickening of capillary wall due to subepithelial immune complexes.
Lupus nephritis Type V (Membranous)
Complete sclerosis of greater than 90% of glomeruli; presents with end-stage renal disease.
Lupus nephritis Type VI (Advanced sclerosing)
A clinicopathologic entity with a triad of dry eyes, dry mouth and other manifestations, such as arthritis.
Sjogren syndrome
Most common and most important autoantibody detected in Sjogren syndrome.
Anti-Ro (SS-A) and anti-La (SS-B) (90%)